The Latest News

No NECC Meningitis-Related Drugs at FHN

10/25/2012

No meningitis-related drugs produced by New England Compounding Center (NECC) in Massachusetts, the company implicated in the recent outbreak of fungal meningitis, have been purchased or used by FHN. The medication from NECC associated with the outbreak, methylprednisolone, has been linked to steroid shots for back pain and has been recalled.

"While FHN has never purchased any of the product involved in the meningitis outbreak, we have purchased two other products from NECC which have been used on a very limited basis that have not been implicated in any infections anywhere in the country. To ensure the health and wellness of our patients, we are contacting the few individuals who received medication produced by NECC to ensure that they are feeling fine and have experienced no complications," said Mike Weaver, Director, Pharmacy Services.

Weaver went on to say that FHN checks with Voluntary Hospital Association (VHA), a large group purchasing organization for U.S. hospitals, before ordering products from compounding pharmacies such as NECC to determine if the pharmacy is on their approved vendor list; NECC was, prior to the recent situation. FHN also verifies that the compounding pharmacy has a valid pharmacy license from the state of Illinois to conduct business in Illinois. Up until the department revoked their license, NECC was current.

Along with many other Illinois healthcare organizations, FHN is shown in the most recent FDA list published in the media as having received two drugs from NECC, one an injectable and the other is an eye-drop. The drugs were most recently used with FHN patients beyond the timeframe generally associated with any reaction to a medication. While all products from NECC have been recalled, neither of the drugs used by FHN have been associated with the meningitis outbreak in any way, and there have been no confirmed reports of infections linked to them or any other products produced by NECC.

Anyone with questions should contact their provider. For more information about the investigation of products from NECC, individuals may also call FDA's Division of Drug Information at 855-543-DRUG (3784) and press * to get the most recent information regarding the multi-state meningitis outbreak, report an adverse event, or speak directly to a pharmacist.

Additional information is available at http://www.cdc.gov/hai/outbreaks/meningitis.html and http://www.fda.gov/drugs.